We are live on ! Find out more
AZN icon

AstraZeneca

1,210 hedge funds and large institutions have $39B invested in AstraZeneca in 2024 Q2 according to their latest regulatory filings, with 149 funds opening new positions, 503 increasing their positions, 330 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more first-time investments, than exits

New positions opened: 149 | Existing positions closed: 69

73% more funds holding in top 10

Funds holding in top 10: 11 → 19 (+8)

52% more repeat investments, than reductions

Existing positions increased: 503 | Existing positions reduced: 330

49% more call options, than puts

Call options by funds: $500M | Put options by funds: $336M

7% more funds holding

Funds holding: 1,135 → 1,210 (+75)

3% more capital inflows, than outflows

Capital inflows: $2.76B | Capital outflows: $2.68B

0.08% more ownership

Funds ownership: 16.03% → 16.11% (+0.08%)

Holders
1,210
Holders Change
+75
Holders Change %
+6.61%
% of All Funds
17.42%
Holding in Top 10
19
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+72.73%
% of All Funds
0.27%
New
149
Increased
503
Reduced
330
Closed
69
Calls
$500​M
Puts
$336​M
Net Calls
+$165​M
Net Calls Change
+$155​M

AZN Hedge Fund Activity: Q2 2024 in Review

1,210 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2024, worth a combined $39B — up 16% from $33.7B a quarter earlier.

Buyers outnumbered sellers: 149 funds opened new AZN positions and 69 closed out — a net gain of 80 holders — while 503 added to existing stakes and 330 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $276M. The largest seller was Wellington Management Group, cutting an estimated $643M.

  • 1,210 institutional investors held AstraZeneca (AZN) as of Q2 2024, up from 1,135 in Q1 2024.
  • Funds reported $39B of AstraZeneca stock for Q2 2024, up 16% quarter-over-quarter.
  • 149 funds opened new AstraZeneca positions in Q2 2024 and 69 closed out, a net change of +80 holders.
  • The largest AstraZeneca buyer in Q2 2024 was T. Rowe Price Associates, an estimated $276M added.
  • The largest AstraZeneca seller in Q2 2024 was Wellington Management Group, an estimated $643M sold.

Based on aggregated 13F filings for Q2 2024.